WEBVTT

1
00:00:02.000 --> 00:00:05.160
Zenagamtide was first known as amycretin.

2
00:00:05.760 --> 00:00:09.480
It brings complementary hormone signals into one engineered

3
00:00:09.480 --> 00:00:13.540
peptide rather than combining two separate medicines.

4
00:00:14.440 --> 00:00:16.700
Novo Nordisk developed it in Denmark.

5
00:00:17.460 --> 00:00:20.900
Agnes Gasiorek and colleagues reported an early oral

6
00:00:20.900 --> 00:00:24.380
study in 2025 conducted at a research unit

7
00:00:24.380 --> 00:00:26.360
in San Antonio, Texas.

8
00:00:27.220 --> 00:00:32.080
The peptide activates GLP-1, amylin and calcitonin

9
00:00:32.080 --> 00:00:37.220
receptors connecting glucose regulation with appetite and fullness.

10
00:00:38.220 --> 00:00:42.180
These structural views show receptor architecture, not a

11
00:00:42.180 --> 00:00:44.140
Zenagamtide binding experiment.

12
00:00:45.000 --> 00:00:48.720
Scientists are studying oral and injectable formulations.

13
00:00:49.520 --> 00:00:54.840
Separate phase 2 analyses included 186 oral participants

14
00:00:54.840 --> 00:01:00.680
and 262 injectable participants with type 2 diabetes.

15
00:01:01.980 --> 00:01:07.160
At 36 weeks, estimated hemoglobin A1c reductions ranged

16
00:01:07.160 --> 00:01:12.460
from 0.9 to 1.7 percentage points in injectable

17
00:01:12.460 --> 00:01:18.120
groups and 0.9 to 1.4 in oral groups.

18
00:01:19.060 --> 00:01:21.160
These are separate route analyses,

19
00:01:21.900 --> 00:01:23.300
not a head-to-head comparison.

20
00:01:24.620 --> 00:01:28.660
Gastrointestinal and serious adverse events were reported.

21
00:01:29.300 --> 00:01:32.400
Long-term safety still requires more evidence.

22
00:01:33.540 --> 00:01:38.220
At the October 13, 2026 cutoff, Zenagamtide remains

23
00:01:38.220 --> 00:01:39.960
investigational.

24
00:01:40.180 --> 00:01:42.160
AMAZE studies obesity,

25
00:01:42.780 --> 00:01:45.600
AMBITION studies type 2 diabetes.

26
00:01:46.960 --> 00:01:49.380
Next, eloralintide.

27
00:01:49.600 --> 00:01:51.080
Peptides in 2.

28
00:01:51.400 --> 00:01:52.580
World Peptide Foundation.

29
00:01:53.000 --> 00:01:54.480
Every experience matters.